Literature DB >> 4041478

Triacylglycerol increase in plasma very low density lipoproteins in cyclophosphamide-treated rabbit: relationship with cholesteryl ester transfer activity.

A M Loudet, N Dousset, B Perret, M Ierides, M Carton, L Douste-Blazy.   

Abstract

We have studied the cholesteryl ester transfer between HDL and VLDL in cyclophosphamide-treated rabbits, in order to explain the abnormal cholesteryl ester partition between these two lipoprotein classes. The hypertriglyceridemia caused by treatment with the drug was associated with cholesteryl ester- and triacylglycerol-rich VLDL and with HDL poor in esterified cholesterol but relatively enriched in triacylglycerol. These two lipoprotein classes were characterized by their chemical composition and by gel filtration chromatography. VLDL particles were slightly larger in size, compared with controls. Different transfer combinations were envisaged between these abnormal lipoproteins and control ones. The transfer study involved the plasma fraction of d greater than 1.21 g/ml containing the cholesteryl ester transfer protein (CETP). It appeared that the chemical composition of lipoproteins was responsible for the level of cholesteryl ester transfer between lipoproteins. Actually, when the cholesteryl ester acceptor lipoproteins (VLDL) were enriched in triacylglycerol, the transfer was enhanced. Therefore, the effect of lipolysis on the transfer has also been explored. Lipoprotein lipase seemed to enhance the transfer of cholesteryl ester from HDL to VLDL when these lipoproteins were normal, but an important decline was obtained when triacylglycerol-rich VLDL were lipolyzed. This study defines the relationship between lipoprotein chemical composition and transfer activity of cholesteryl ester from HDL to VLDL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4041478     DOI: 10.1016/0005-2760(85)90142-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

Review 1.  Interaction of lipid transfer protein with plasma lipoproteins and cell membranes.

Authors:  R E Morton
Journal:  Experientia       Date:  1990-06-15

2.  Acrolein consumption induces systemic dyslipidemia and lipoprotein modification.

Authors:  Daniel J Conklin; Oleg A Barski; Jean-Francois Lesgards; Peter Juvan; Tadeja Rezen; Damjana Rozman; Russell A Prough; Elena Vladykovskaya; SiQi Liu; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Toxicol Appl Pharmacol       Date:  2009-12-23       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.